The Year In New Drugs
FDA’s drug approvals in 2014 were remarkable for both their quantity and quality
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
February 2, 2015 Cover
Volume 93, Issue 5
FDA’s drug approvals in 2014 were remarkable for both their quantity and quality
Cover image:
Credit:
FDA’s drug approvals in 2014 were remarkable for both their quantity and quality
Future executive director and CEO discusses challenges and opportunities facing the society
Agency’s latest Toxics Release Inventory shows green chemistry, pollution-prevention efforts are paying dividends
Materials research advances promise to make the energy storage device a complement to batteries
Reimbursements for the overhead costs of facilities and administrative support for grant-funded inquiry are controversial and often misunderstood
Private equity firm SK is scaling up its buy-and-hold strategy
Method exploits pristine graphene’s knack for stabilizing interface between immiscible liquids